AKT1 and chronic myelogenous leukemia, BCR-ABL1 positive: Schätzl et al. [177] demonstrated that Tyrosine kinase inhibitors (TKIs), such as nilotinib and imatinib, the gold standard treatment of chronic myeloid leukemia (CML), can induce autophagy in CML cells by inhibiting the PI3K-Akt-mTORC1 signaling pathway.